Physician profile
Thomas B Repas
NPI 1134180516
$22,167.10
in general payments reported to CMS, 2019-2025
25 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,785 · 2020: $4,382 · 2021: $3,039 · 2022: $159 · 2023: $5,700 · 2024: $340 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,590 · Food and Beverage: $1,669 · Travel and Lodging: $1,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,590.00 |
| Food and Beverage | $1,669.25 |
| Travel and Lodging | $1,543.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $7,430.08 | 2019-2025 | Evenity, Prolia, Prolia |
| Regeneron Healthcare Solutions, INC. | $5,524.51 | 2022-2024 | Evkeeza |
| Merck Sharp & Dohme LLC | $3,600.11 | 2019-2021 | |
| Novo Nordisk INC | $2,266.40 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Kaneka Medical America LLC | $1,798.50 | 2020-2021 | |
| Corcept Therapeutics | $473.07 | 2019-2025 | Korlym |
| Lilly USA, LLC | $208.08 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $134.02 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $129.78 | 2019-2025 | Breztri |
| Medtronic, INC. | $101.37 | 2021-2025 | Minimed 780g, Minimed 770g |
| Xeris Pharmaceuticals, INC. | $85.45 | 2025 | Recorlev |
| Alexion Pharmaceuticals, INC. | $63.38 | 2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $53.02 | 2019-2024 | |
| Abbott Laboratories | $40.82 | 2022-2023 | Freestyle Libre |
| Philips North America LLC | $40.78 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $37.07 | 2023-2025 | Isturisa, Signifor Lar |
| Ucb, INC. | $28.95 | 2025 | Bimzelx |
| Lundbeck LLC | $27.68 | 2023 | Rexulti |
| Astellas Pharma US INC | $24.88 | 2025 | Veozah |
| Madrigal Pharmaceuticals | $18.75 | 2025 | Rezdiffra |
| Chiesi USA, INC. | $17.69 | 2025 | Juxtapid |
| Kyowa Kirin, INC. | $17.59 | 2024 | Crysvita |
| Mimedx Group, INC. | $16.86 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.04 | 2023 | |
| Abbvie INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Repas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.